| 41/108 | US=13 / Biol/Mol Pecorino L. Growth factor signaling and oncogenes. In: ___. Molecular biology of cancer: mechanisms, targets, and therapeutics. 2nd ed. Oxford: Oxford University Press, 2008. p. 69-94. ISBN 978-0-19-921148-7. FATORES DE CRESCIMENTO; SINALIZACAO; ONCOGENES; FATOR DE CRESCIMENTO EPIDERMICO; AUTOFOSFORILACAO; TRANSLOCACAO DE PROTEINAS ESPECIFICAS; ATIVACAO DO GENE RAS; ATIVACAO DO GENE RAF; CASCATA DE MAP QUINASE; REGULACAO DOS FATORES DE TRANSCRICAO; SINALIZACAO CELULAR; COMPORTAMENTO CELULAR; RETROVIRUS; TRANSDUTORES DE SINAL INTRACELULAR; FATORES DE TRANSCRICAO; MECANISMOS DE ATIVACAO ONCOGENICA; INIBIDORES DA QUINASE; DROGAS ANTI-EGFR; DROGAS ANTI-RECEPTORES DO FATOR DE CRESCIMENTO EPIDERMICO |
| 42/108 | US=13 / Biol/Mol Pecorino L. The cell cycle. In: ___. Molecular biology of cancer: mechanisms, targets, and therapeutics. 2nd ed. Oxford: Oxford University Press, 2008. p. 95-112. ISBN 978-0-19-921148-7. CICLO CELULAR; CICLINAS; QUINASES DEPENDENTES DE CICLINA; MECANISMOS DE REGULACAO CDK; CONTROLE G1; CONTROLE G2; CHEKPOINT MITOTICO; CINASES AURORA; CANCER; CICLINA DEPENDENTE DE INIBIDORES DE QUINASE; ALVOS CELULARES |
| 43/108 | US=35 / Biol/Mol Bafico A, Grumolato L, Aaronson SA. Oncogenes and signal transduction. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 17-30. ISBN 978-1-4160-3703-3. ONCOGENE; TRANSDUCAO DE SINAL; RECEPTORES DE TIROSINA-QUINASE; RECEPTORES DE CITOCINA; NEUROTRANSMISSORES; SINALIZACAO WNT; TERAPIA DO CANCER |
| 44/108 | US=2 / Tórax Shames DS, Sato M, Minna JD. The molecular genetics of lung. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 61-83. ISBN 978-1-4051-5112-2. GENETICA MOLECULAR DO PULMAO; BREVE HISTORIA DA GENETICA DO CANCER; GENETICA MOLECULAR DO PULMAO; GENES SUPRESSORES DE TUMORES; QUINASE DE TIROSINA RECEPTORA |
| 45/108 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 46/108 | US=47 / Câncer Shakalya K, Mahadevan D. Antiproliferation inhibitors targeting aurora kinases. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 243-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES ANTI-PROLIFERACAO; AURORA QUINASE; MITOSE; CICLO CELULAR; PROTO-ONCOGENES; INIBIDORES DA PROTEINA-QUINASE; ANEUPLOIDIA; CITOCINESE |
| 47/108 | US=49-D / Câncer Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase ron in tumor growth and metastasis. In: Woude GFV, Klein G. Advances in cancer research. v.100. Amsterdam: Elsevier, 2008. p. 1-33. ISBN 978-0-12-374358-9. RECEPTOR MET; TIROSINA-QUINASE; CRESCIMENTO TUMORAL; METASTASE; CANCER; RON. ESTRUTURA; RON. FUNCAO; RON (REGIAO ORGANIZADORA DE NUCLEOLO); MACROFAGOS; TRANSICAO EPITELIAL MESENQUIMAL; TUMORIGENESE; ANGIOGENESE; EXPRESSAO EM TUMORES HUMANOS; CANCER DE MAMA; CANCER DE PROSTATA; CANCER DE PANCREAS; CANCER DE RIM; CANCER DE BEXIGA; CANCER DE OVARIO; CANCER DE PULMAO; CANCER GASTROINTESTINAL; CANCER DE FIGADO; CANCER. TERAPIA |
| 48/108 | US=64 / Câncer Harvey RD, Silberman J, Lonmial S. The PI3 kinase/akt pathway as a therapeutic target in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 309-22. (Comtemporary Hematology) ISBN 978-1-934115-82-4. PI3 QUINASE; AKT; TERAPEUTICO NO MIELOMA MULTIPLO; MIELOMA MULTIPLO. TERAPIAS |
| 49/108 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 50/108 | US=67 / Biol/Mol Atieh DM, Vahdat LT. Targeted therapy for beast cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 309-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE MAMA; TERAPIA-ALVO; TRASTUZUMABE; HER-2; MICROARRAY; BEVACIZUMABE; VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; LAPATINIBE; ANTICORPOS MONOCLONAIS; INIBIDOR DA TIROSINA QUINASE |
| 51/108 | US=67 / Biol/Mol Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225 |
| 52/108 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |
| 53/108 | US=69 / Câncer Jabbour E, Cortes J, Kantarjian H. Targeted therapy in chronic myeloid leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 87-99. ISBN 978-1-60327-423-4. TERAPIA-ALVO NA LEUCEMIA MIELOIDE CRONICA; LEUCEMIA MIELOIDE CRONICA; INIBIDOR DA TIROSINA QUINASE; RESISTENCIA; BCR-ABL |
| 54/108 | US=69 / Câncer Wedgwood A, Younes A. Targeted therapy in lymphoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 157-82. ISBN 978-1-60327-423-4. TERAPIA-ALVO NO LINFOMA; ANTICORPO; LINFOMA; ANTIGENO; RECEPTOR; INIBIDOR; QUINASE |
| 55/108 | US=69 / Câncer Davies M, Patel S, Kim KB. Targeted therapy in melanoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 183-211. ISBN 978-1-60327-423-4. TERAPIA-ALVO EM PACIENTES COM MELANOMA; MELANOMA; TRANSDUCAO DE SINAL; QUINASE DO RECEPTOR; B-RAF; N-RAS; PTEN; MAP QUINASE; NFKB; ANTIOGENESIS; IMMUNOTARGETING |
| 56/108 | US=58 / Câncer Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: ___. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 199-213. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; P21; CICLINA DEPENDENTE DE QUINASE; G1 RESPOSTA CHECKPOINT; PARADA DO CICLO CELULAR; TRANSATIVACAO; PARADA DO CICLO GENE |
| 57/108 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |
| 58/108 | US=80 / Biol/Mol Gjertsen BT, Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute myeloid leukemia. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 161-87. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7. LEUCEMIA MIELOIDE AGUDA; BIOMARCADORES; PHARMACOPROTEOMICS; ACIDO TRANS-RETINOICO; INIBIDORES DE QUINASE DE TIROSINA; HISTONA DEACETILASE INIBIDORES; INIBIDORES DE PROTEASSOMA |
| 59/108 | US=84 / Biol/Mol Liu F. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: component hardware for transformig growth factor-B signal transduction: regulation of smad activity by phosphorylation. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 105-23. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. TGF-B; SMAD; FOSFORILACAO; FOSFATASE; QUINASE DO RECEPTOR; MAP QUINASE; CDK; CANCER |
| 60/108 | US=84-A / Biol/Mol Ungefroren H. Transformig growth factor-B in developing and advanced cancers: TGF-B signaling and biglycan in pancreatic cancer. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 51-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. CANCER DE PANCREAS; RECEPTOR; SMAD; BIGLICAM; PARAGEM DO CRESCIMENTO; DANO DO DNA-45B; P38 CINASE DE PROTEINA ACTIVADA POR MITOGENIO; NADPH OXIDASE; PROTEINA QUINASE C; FACTOR DE CRESCIMENTO TRANSFORMANTE-B |